Cargando…

Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2

Effective treatment or vaccine is not yet available for combating SARS coronavirus 2 (SARS-CoV-2) that caused the COVID-19 pandemic. Recent studies showed that two drugs, Camostat and Nafamostat, might be repurposed to treat COVID-19 by inhibiting human TMPRSS2 required for proteolytic activation of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Haixia, Du, Wenhao, Song, Menghua, Liu, Qing, Herrmann, Andreas, Huang, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Research Network of Computational and Structural Biotechnology 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809394/ https://www.ncbi.nlm.nih.gov/pubmed/33505639 http://dx.doi.org/10.1016/j.csbj.2020.12.035

Ejemplares similares

Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat
por: Sun, Gaohui, et al.
Publicado: (2021)

Inhibition of Listeria Monocytogenes HtrA Protease with Camostat, Gabexate and Nafamostat Mesylates and the Binding Mode of the Inhibitors
por: C, Amrutha M, et al.
Publicado: (2023)

Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat
por: Hempel, Tim, et al.
Publicado: (2020)

Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations
por: Ramakrishnan, Jaganathan, et al.
Publicado: (2021)

Camostat Does Not Inhibit the Proteolytic Activity of Neutrophil Serine Proteases
por: Assylbekova, Akmaral, et al.
Publicado: (2022)

RAndomized Clinical Trial Of NAfamostat Mesylate, A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor, in Patients with COVID-19 Pneumonia
por: Seccia, Teresa Maria, et al.
Publicado: (2023)

Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?
por: Bittmann, Stefan, et al.
Publicado: (2020)

Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach
por: Sonawane, Kailas D., et al.
Publicado: (2021)

Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions
por: Weiss, Johanna, et al.
Publicado: (2021)

Structural modeling and analysis of the SARS-CoV-2 cell entry inhibitor camostat bound to the trypsin-like protease TMPRSS2
por: Escalante, Diego E., et al.
Publicado: (2021)

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
por: Hoffmann, Markus, et al.
Publicado: (2020)

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
por: Hoffmann, Markus, et al.
Publicado: (2021)

Pharmacokinetics of Nafamostat, a Potent Serine Protease Inhibitor, by a Novel LC-MS/MS Analysis
por: Oh, Hyeon Seok, et al.
Publicado: (2022)

The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells
por: Yamaya, Mutsuo, et al.
Publicado: (2015)

Nafamostat mesylate, a serine protease inhibitor, demonstrates novel antimicrobial properties and effectiveness in Chlamydia-induced arthritis
por: Inman, Robert D, et al.
Publicado: (2012)

Computational screening of camostat and related compounds against human TMPRSS2: A potential treatment of COVID-19
por: Sharma, Tanuj, et al.
Publicado: (2022)

Intracellular autoactivation of TMPRSS11A, an airway epithelial transmembrane serine protease
por: Zhang, Ce, et al.
Publicado: (2020)

Magnesium treatment on methylation changes of transmembrane serine protease 2 (TMPRSS2)
por: Fan, Lei, et al.
Publicado: (2021)

Association of the Transmembrane Serine Protease-2 (TMPRSS2) Polymorphisms with COVID-19
por: Posadas-Sánchez, Rosalinda, et al.
Publicado: (2022)

A Serine Protease Inhibitor, Camostat Mesilate, Suppresses Urinary Plasmin Activity and Alleviates Hypertension and Podocyte Injury in Dahl Salt-Sensitive Rats
por: Iwata, Yasunobu, et al.
Publicado: (2023)

A mutation in the serine protease TMPRSS4 in a novel pediatric neurodegenerative disorder
por: Lahiry, Piya, et al.
Publicado: (2013)

Expression of trans-membrane serine protease 3 (TMPRSS3) in the human organ of Corti
por: Liu, Wei, et al.
Publicado: (2018)

Host Serine Proteases TMPRSS2 and TMPRSS11D Mediate Proteolytic Activation and Trypsin-Independent Infection in Group A Rotaviruses
por: Sasaki, Michihito, et al.
Publicado: (2021)

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
por: Gunst, Jesper D., et al.
Publicado: (2021)

Retinal expression of the serine protease matriptase-2 (Tmprss6) and its role in retinal iron homeostasis
por: Gnana-Prakasam, Jaya P., et al.
Publicado: (2014)

TMPRSS4, a type II transmembrane serine protease, as a potential therapeutic target in cancer
por: Kim, Semi
Publicado: (2023)

Epithelial Sodium Channel-Mediated Sodium Transport Is Not Dependent on the Membrane-Bound Serine Protease CAP2/Tmprss4
por: Keppner, Anna, et al.
Publicado: (2015)

Camostat mesilate therapy for COVID-19
por: Uno, Yoshiharu
Publicado: (2020)

The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19
por: Li, Kun, et al.
Publicado: (2021)

Posttranslational modifications of serine protease TMPRSS13 regulate zymogen activation, proteolytic activity, and cell surface localization
por: Martin, Carly E., et al.
Publicado: (2021)

Transmembrane serine protease TMPRSS2 implicated in SARS-CoV-2 infection is autoactivated intracellularly and requires N-glycosylation for regulation
por: Zhang, Yikai, et al.
Publicado: (2022)

Knockdown of TMPRSS3, a Transmembrane Serine Protease, Inhibits Proliferation, Migration, and Invasion in Human Nasopharyngeal Carcinoma Cells
por: Wang, Jun-Ying, et al.
Publicado: (2018)

Computational Analysis of Missense Variants in the Human Transmembrane Protease Serine 2 (TMPRSS2) and SARS-CoV-2
por: Saih, Asmae, et al.
Publicado: (2021)

Transmembrane protease serine 2 (TMPRSS2) rs75603675, comorbidity, and sex are the primary predictors of COVID-19 severity
por: Villapalos-García, Gonzalo, et al.
Publicado: (2022)

Electrostatic recognition in substrate binding to serine proteases
por: Waldner, Birgit J., et al.
Publicado: (2018)

A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19
por: Kitagawa, Junsaku, et al.
Publicado: (2021)

Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2
por: Ianevski, Aleksandr, et al.
Publicado: (2021)

Transmembrane protease, serine 4 (TMPRSS4) is upregulated in IPF lungs and increases the fibrotic response in bleomycin-induced lung injury
por: Valero-Jiménez, Ana, et al.
Publicado: (2018)

Deletion of the serine protease CAP2/Tmprss4 leads to dysregulated renal water handling upon dietary potassium depletion
por: Keppner, Anna, et al.
Publicado: (2019)

In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2)
por: Barge, Sagar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v0s9dek0d0qm4v1ca75nom780h